Homovanillic Acid (HVA)

← Back to Lab Reference Library

Category: Advanced & Specialty  |  Also known as: HVA, Dopamine Metabolite, Urinary HVA

1. What This Test Measures

Homovanillic acid is the principal end-product of dopamine catabolism. After dopamine is released from nerve terminals and acts at dopaminergic receptors, it is broken down sequentially by monoamine oxidase (MAO) and catechol-O-methyltransferase (COMT), ultimately producing HVA, which is excreted in the urine. Measuring urinary HVA provides an indirect but quantifiable window into dopaminergic system activity: how much dopamine is being made, used, and cleared.

In functional medicine, HVA testing serves two roles. The first is oncological: HVA is a validated tumor marker for catecholamine-secreting neoplasms, particularly neuroblastoma (in which HVA is often dramatically elevated alongside vanillylmandelic acid, VMA) and pheochromocytoma. Any markedly elevated HVA must prompt evaluation for these tumors before a functional interpretation is applied. The second role is neurofunctional: in patients without tumor evidence, HVA levels reflect the health and productivity of the dopaminergic system, informing assessment of mood regulation, executive function, motivation, focus, reward processing, and movement control. HVA is often ordered as part of the Organic Acids Test (OAT) or as a standalone 24-hour urine catecholamine panel.

2. Optimal Range and Clinical Thresholds

HVA (24-hr urine, mg/day)	Interpretation
1.4 to 8.8 mg/day	Standard reference range (adults); optimal toward mid-range with adequate dopaminergic tone
Below 1.4 mg/day	Low: suggests reduced dopamine synthesis; evaluate precursor status, cofactors, and stress history
8.8 to 20 mg/day	Mildly elevated: may reflect stimulant medication, high-tyrosine diet, or stress-driven hypercatecholaminemia; repeat with dietary restriction
Above 20 mg/day	Significantly elevated: rule out neuroblastoma, pheochromocytoma, or paraganglioma; specialist referral indicated

Reference ranges vary by laboratory and collection method. 24-hour urine with acidified preservative is the gold standard. Always interpret alongside VMA, metanephrines, and the clinical picture before attributing elevation to non-oncological causes.

3. Dopamine Physiology and Why HVA Matters

Dopamine is synthesized from tyrosine in a two-step pathway: tyrosine hydroxylase (requiring iron and tetrahydrobiopterin) converts tyrosine to L-DOPA, then DOPA decarboxylase (requiring pyridoxal-5-phosphate, the active form of B6) converts L-DOPA to dopamine. Once released, dopamine is catabolized by MAO then COMT, producing HVA. Genetic polymorphisms in COMT, particularly the Val158Met variant, significantly affect the rate of dopamine degradation. COMT slow metabolizers (Met/Met genotype) catabolize dopamine more slowly, maintain higher synaptic dopamine, and produce less HVA per unit of dopamine synthesized.

Dopamine governs motivation and reward processing, working memory, attention and focus, movement initiation, and pituitary regulation of prolactin, growth hormone, and TSH. Inadequate dopaminergic tone (low HVA) produces amotivation, anhedonia, brain fog, and poor concentration. Excessive dopamine activity (high HVA) can produce anxiety, racing thoughts, and impulsivity.

4. Clinical Causes of Low HVA

• Tyrosine or phenylalanine deficiency: dopamine synthesis begins with tyrosine; inadequate dietary protein or impaired phenylalanine-to-tyrosine conversion limits the substrate pool, reducing HVA output
• Vitamin B6 (pyridoxal-5-phosphate) deficiency: DOPA decarboxylase is absolutely B6-dependent; B6 deficiency impairs the conversion of L-DOPA to dopamine; this is a common and frequently missed nutritional cause of low HVA
• Iron deficiency: tyrosine hydroxylase requires iron as a cofactor; iron-deficient states reduce the rate of dopamine synthesis and produce low HVA, partly explaining cognitive and motivational symptoms of iron-deficiency anemia before frank anemia develops
• Chronic catecholamine burnout: prolonged psychological or physiological stress drives sustained catecholamine output, eventually depleting the dopamine synthetic pool; HVA, VMA, and clinical energy and motivation are all reduced
• Parkinson disease and Lewy body pathology: progressive loss of dopaminergic neurons in the substantia nigra produces declining HVA as the disease advances; HVA reduction precedes clinical motor deterioration
• MAO inhibitor medications: MAOIs block the first step of dopamine catabolism, reducing HVA production despite normal or increased dopamine synthesis; HVA cannot be interpreted without knowing medication status

5. Clinical Causes of Elevated HVA

• Catecholamine-secreting tumors (must exclude first): neuroblastoma, pheochromocytoma, and paraganglioma produce massive catecholamine output; HVA above 20 mg/day in an adult warrants imaging and specialist evaluation
• Stimulant medications: amphetamine-based ADHD medications increase dopamine release and turnover, elevating HVA; methylphenidate has a smaller effect
• Dietary vanillin interference: vanillin in vanilla-containing foods shares structural similarity with HVA and can produce false elevations on colorimetric assays; 48 to 72 hour dietary restriction before collection is mandatory
• High tyrosine intake: large tyrosine supplementation doses increase the substrate pool for dopamine synthesis, transiently elevating HVA
• Acute psychological stress: acute stress activates the sympathoadrenal system, driving a surge in catecholamine synthesis and turnover that transiently elevates HVA

6. How to Optimize HVA and Dopaminergic Function

7. Related Lab Tests

8. Clinical Perspective

9. Frequently Asked Questions